---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction"
date: 2026-02-05 18:57:35 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-25489
original_published: 2023-11-17 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 17, 2023 00:00 UTC
**Document Number:** 2023-25489

## Summary

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of July 8, 2022. The document announced the determination of the regulatory review period for ROZLYTREK INJECTION (entrectinib) for purposes of patent extension. The document was published with an incorrect dosage form. This notice corrects the dosage form of the drug product.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/17/2023-25489/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection)
- API: https://www.federalregister.gov/api/v1/documents/2023-25489

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
